title: Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
abstract: BACKGROUND
  Liver biopsy is the reference standard to assess liver fibrosis in chronic hepatitis C.
  
  
  OBJECTIVE
  To validate and compare the diagnostic performance of non-invasive tests for prediction of liver fibrosis severity and assessed changes in extracellular matrix markers after antiviral treatment.
  
  
  METHODS
  The performances of Forns' score, AST to platelet ratio index (APRI), FIB-4 index and Enhanced Liver Fibrosis (ELF) score were validated in 340 patients who underwent antiviral therapy. These scores were determined 24 weeks after treatment in 161 patients.
  
  
  RESULTS
  Forns' score, APRI, FIB-4 and ELF score showed comparable diagnostic accuracies for significant fibrosis [area under the receiver operating characteristic curve (AUROC) 0.83, 0.83, 0.85 and 0.81, respectively]. To identify cirrhosis, FIB-4 index showed a significantly better performance over APRI and ELF score (AUROC 0.89 vs. 0.83 and 0.82, respectively). ELF score decreased significantly in patients with sustained virological response (SVR) (P < 0.0001) but remained unchanged in nonresponders. Non-1 hepatitis C virus (HCV) genotype, baseline lower HCV RNA, glucose, hyaluronic acid and higher cholesterol levels were independently associated with SVR.
  
  
  CONCLUSIONS
  Simple panel markers and ELF score are accurate at identifying significant fibrosis and cirrhosis in chronic hepatitis C. A decrease in ELF score after antiviral treatment reflects the impact of viral clearance in hepatic extracellular matrix and probably in the improvement of liver fibrosis.
authors.affiliation: Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain.
authors.forename: S M
authors.initials: SM
authors.lastname: Martinez
authors.forename: G
authors.initials: G
authors.lastname: Fernández-Varo
authors.forename: P
authors.initials: P
authors.lastname: González
authors.forename: E
authors.initials: E
authors.lastname: Sampson
authors.forename: M
authors.initials: M
authors.lastname: Bruguera
authors.forename: M
authors.initials: M
authors.lastname: Navasa
authors.forename: W
authors.initials: W
authors.lastname: Jiménez
authors.forename: J M
authors.initials: JM
authors.lastname: Sánchez-Tapias
authors.forename: X
authors.initials: X
authors.lastname: Forns
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D004812:Epidemiologic Methods; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology*; D008103:Liver Cirrhosis / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin